The global renal diseases market has been growing at an incremental pace and is expected to attain USD 14291.2 Mn by the end of 2023, reveals Market Research Future (MRFR) in a minutely analyzed research report. The market has been growing persistently on account of rising prevalence of renal diseases across the globe which necessitates diagnosis and treatment. The rise in the geriatric population who are at more risk of kidney failures and other renal diseases boost the growth of the market. High prevalence of diabetes is also a critical factor in stimulating the growth of the market. Diabetes remains a significant risk factor for renal diseases, especially kidney failure. Initiatives undertaken by governments of various countries to increase awareness and also various healthcare schemes launched for the prevention and treatment of renal diseases spur the growth of the market. Significant expansion of the healthcare industry, increase in Clinical trials and R&D activities are other driving factors for the growth of the market. However, the market growth might be restrained by high costs of treatment.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/3167
Technological advancement and new product development are expected to provide opportunities for growth over the forecast period. These factors in conjunction will shape the global renal disease market and help it achieve a CAGR of 6.3% over the forecast period of 2017-2023.
The global renal disease market has been segmented based on type, diagnosis, and treatment. By type, the market has been segmented into acute kidney problems, chronic kidney diseases, and others. The acute kidney problems segment has been further segmented into Prerenal, Post renal, and Renal. By diagnosis, the market has been segmented into Blood tests, Urine tests, imaging tests, removing a sample of kidney tissue for testing, and others. The blood tests segment has been further segmented into Serum Creatinine, Glomerular Filtration Rate (GFR), Blood Urea Nitrogen (BUN), and fasting blood glucose test. The urine test segment has been further segmented into Urinalysis, Protein urine test, Microalbuminuria test, Creatinine Clearance test. The imaging test segment has been further segmented into ultrasound and CT scan. By treatment, the market has been segmented into Medications, Dialysis, Kidney transplant, Surgery, Diet and others. The medication segment has been further segmented into High blood pressure medications, Medications to lower cholesterol levels, Medications to treat anemia, Medications to relieve swelling, and Medications to protect your bones. The dialysis segment has been further segmented into Hemodialysis, and Peritoneal dialysis. The kidney transplant segment has been further segmented into Deceased-donor kidney transplant, Living-donor kidney transplant, and Pre-emptive kidney transplant. The surgery segment has been further segmented into Nephrectomy and radical nephrectomy, nephron-sparing surgery (NSS), nephrolithotripsy, extracorporeal shock wave lithotripsy (ESWL), and others.
Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/3167
The global renal disease market spans across the regions of the Americas, Europe, Asia Pacific, and the Middle East & Africa. The Americas account for the largest share of the global renal disease market followed by Europe. The America market for renal disease is dominated by the US owing to high health care spending, favorable reimbursement scenario and the presence of a large patient population in the region. Europe market is going strong on account of a robust healthcare sector and availability of funds for R&D. Germany, France, Italy, UK, and Spain are the key contributors to the Europe market for renal diseases. Asia Pacific is expected to grow at a relatively faster rate, led by Japan, China, India, and South Korea. The Middle East & Africa market is expected to exhibit moderate growth over the forecast period and will be led by the Gulf economies of UAE, Saudi Arabia, and others.
The key players in the global renal disease market include Abbott (US), Baxter (US), Keryx Biopharmaceuticals, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Amgen Inc. (US), Bristol-Myers Squibb Company (US), NephroGenex, Inc. (US), Pfizer Inc.(US), Shire Pharmaceuticals Limited (Republic of Ireland), and others.
In August 2018, Nephros subsidiary Specialty Renal Products (SRP) agreed with HemoCleanse Technologies to develop and commercialize rights for a dialysate regeneration and filtration system for the treatment of renal disease. According to the agreement, SRP will be the manufacturer of record for licensors of the technology outside of renal disease.
Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/3167
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312